MedTrace Logo

Atazanavir for HIV Infected Individuals: An Early Access Program

NCT00046345 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2011-04-14

No results posted yet for this study

Summary

The purpose of this clinical research study is to provide atazanavir to patients infected with human immunodeficiency virus (HIV) whose antiviral medications are no longer working to control HIV activity within the body and who are unable to create a new treatment regimen using other available anti-HIV drugs, because of either side effects or treatment failure previously taken. The safety of this treatment will also be studied.

Conditions

  • HIV Infections

Interventions

DRUG

Atazanavir (BMS-232632)

Sponsors & Collaborators

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Completion
2003-07-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00046345 on ClinicalTrials.gov